Msi-1 is a Predictor of Survival and a Novel Therapeutic Target in Colon Cancer
Department of General Surgery, Shanghai Jiaotong University, Shanghai, People's Republic of China. Annals of Surgical Oncology
(Impact Factor: 3.93).
03/2011; 18(7):2074-83. DOI: 10.1245/s10434-011-1567-9
Musashi1 (Msi-1), a neural RNA-binding protein, plays an important role in regulating cell differentiation in precursor cells. Recently, aberrant expression of Msi-1 has been detected in several malignancies. However, its role in the progression of colon cancer is largely unknown.
We used Western blotting to examine Msi-1 protein expression in 8 cases of primary colon cancer lesions and paired normal colonic mucosa. Msi-1 expression and clinicopathological significance were determined by immunohistochemical staining in a tissue microarray (TMA) containing 203 cases of primary colon cancer paired with noncancerous tissue and 66 lymph node metastasis (LNM) tissues. RNAi was used to analyze the biological function of Msi-1 in vitro.
LNM tissue exhibited a striking increase in Msi-1 expression when compared with primary colon cancer and adjacent normal mucosa (87.9% vs. 64.5% vs. 16.7%, P < .001). Overexpression of Msi-1 was associated with higher clinical stage, T stage, lymph node metastasis, presence of distant metastasis, and Ki-67 positivity. Msi-1 served as an independent prognostic marker whose expression levels correlated with poorer metastasis-free survival (MFS) (HR 5.4; P < .001) and poorer overall survival (OS) (HR 3.8; P < .001). Msi-1 silencing significantly inhibited proliferation ability and attenuated the migration and invasion activity of colon cancer cells.
Our study provides the basis to explore the use of Msi-1 as a novel prognostic biomarker in colon cancer patients. Aberrant overexpression of Msi-1 during metastasis of colon cancer also suggests that it is a potential therapeutic target.
Available from: PubMed Central
- "The human genome encodes approximately 30 DEAD-box RNA helicases, which metabolize ATP to unwind RNA and/or remodel RNA-protein complexes (Putnam and Jankowsky, 2013). These proteins can also clamp onto RNA, thus serving as a scaffold for the assembly of larger RNA-protein complexes (Linder and Jankowsky, 2011). RNA helicases perform a diverse variety of functions in the cell, and mutations in these genes have previously been linked to cancer (Abdelhaleem, 2004). "
[Show abstract] [Hide abstract]
ABSTRACT: Medulloblastoma, the most common malignant brain tumor in children, is a disease whose mechanisms are now beginning to be uncovered by high-throughput studies of somatic mutations, mRNA expression patterns, and epigenetic profiles of patient tumors. One emerging theme from studies that sequenced the tumor genomes of large cohorts of medulloblastoma patients is frequent mutation of RNA binding proteins. Proteins which bind multiple RNA targets can act as master regulators of gene expression at the post-transcriptional level to co-ordinate cellular processes and alter the phenotype of the cell. Identification of the target genes of RNA binding proteins may highlight essential pathways of medulloblastomagenesis that cannot be detected by study of transcriptomics alone.Furthermore, a subset of RNA binding proteins are attractive drug targets. For example, compounds that are under development as anti-viral targets due to their ability to inhibit RNA helicases could also be tested in novel approaches to medulloblastoma therapy by targeting key RNA binding proteins. In this review, we discuss a number of RNA binding proteins, including Musashi1 (MSI1), DEAD (Asp-Glu-Ala-Asp) box helicase 3 X-linked (DDX3X), DDX31, and cell division cycle and apoptosis regulator 1 (CCAR1), which play potentially critical roles in the growth and/or maintenance of medulloblastoma.
Available from: erc.endocrinology-journals.org
- "As vascular and neural infiltrations are known to be ominous prognostic factors, their identification has great clinical relevance. Increasing evidence shows that perineural invasion or the neural cell adhesion molecule might be a prognostic factor for various cancers, such as bile duct cancer (Seki et al. 1993, Kayahara et al. 1994), gallbladder cancer (Seki et al. 1995), breast cancer (Lo et al. 1997), esophageal cancer (Tanaka et al. 1998), pancreatic cancer (Pour et al. 2003, Levy et al. 2006, Kayahara et al. 2007), prostate cancer (Li et al. 2003), and colorectal cancer (Gavert et al. 2005, Zhou et al. 2009, Li et al. 2011). "
[Show abstract] [Hide abstract]
ABSTRACT: Glial cell line-derived neurotrophic factor (GDNF), a potent neurotrophic factor, has been identified to affect cancer cell metastasis and invasion. However, the molecular mechanisms underlying GDNF-induced colon cancer cell migration remains unclear. GDNF is found to be positively correlated with malignancy in human colon cancer patients. The migratory activities of 2 human colon cancer cell lines, HCT-116 and SW480, were found to be enhanced in the presence of human GDNF. The expression of vascular endothelial growth factor (VEGF) was also increased in response to GDNF stimulation, along with VEGF mRNA expression and transcriptional activity. The enhancement of GDNF-induced cancer cell migration was antagonized by a VEGF-neutralized antibody. Our results also showed that the expression of VEGF receptor-1 (VEGFR-1) was increased in response to GDNF stimulation, whereas GDNF-induced cancer cell migration was reduced by a VEGFR inhibitor. The GDNF-induced VEGF expression was regulated by the p38 and PI3 kinase/Akt signaling pathways. Treatment with GDNF increased nuclear HIF-1α accumulation and its transcriptional activity in a time-dependent manner. Moreover, GDNF increased HRE-containing VEGF promoter transcriptional activity but not the HRE-deletion VEGF promoter construct. Inhibition of HIF-1α by a pharmacological inhibitor or dominant-negative mutant reduced the GDNF-induced migratory activity in human colon cancer cells. These results indicate that GDNF enhances the migration of colon cancer cells by increasing VEGF/VEGFR interaction, which is mainly regulated by the p38, PI3 kinase/Akt, and HIF-1α signaling pathways.
Available from: Mai Yamauchi
[Show abstract] [Hide abstract]
ABSTRACT: Infiltrative growth pattern at the tumor margin has been associated with shorter patient survival. However, little is known about the prognostic significance of tumor growth pattern, independent of tumoral molecular alterations and other histologic features.
Utilizing a database of 1139 colon and rectal cancer patients in two prospective cohort studies, histologic features including tumor growth pattern, tumor differentiation, lymphocytic reaction, mucinous component, and signet ring cell component were recorded by a single pathologist. Cox proportional hazard model was used to compute mortality hazard ratio, adjusting for clinical, pathologic, and tumor molecular features, including microsatellite instability, the CpG island methylator phenotype, long interspersed nucleotide element 1 (LINE-1) methylation, and KRAS, BRAF, and PIK3CA mutations.
Among 1139 colorectal cancers, we observed expansile growth pattern in 372 tumors (33%), intermediate growth pattern in 610 tumors (54%), and infiltrative growth pattern in 157 tumors (14%). Compared to patients with expansile growth pattern, those with infiltrative growth pattern experienced shorter cancer-specific survival (log rank P < 0.0001; multivariate hazard ratio 1.74; 95% confidence interval 1.22-2.47) and overall survival (log rank P < 0.0001; multivariate hazard ratio 1.78; 95% confidence interval 1.33-2.39). The prognostic association of infiltrative growth pattern was confined to patients with stage I-III disease (P (interaction) with stage = 0.0001).
Infiltrative growth pattern was associated with worse prognosis among stage I-III colorectal cancer patients, independent of other clinical, pathologic, and molecular characteristics.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.